Business
CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later
About this update from Calcimedica, Inc.
[{"type":"text","content":"Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year\nFirst patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025\nLA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. (\"CalciMedica or the Company\") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.\n\n \n \n \n \n \n \n\n \n\"CalciMedica continues to progress steadily with the successful execution of multiple milestones across our pipeline. In the second quarter, we completed enrollment in our Phase 2b CARPO trial in patients with AP and subsequently announced positive topline data, which met our primary objective and further support Auxora's potential as an effective treatment for critically ill patients with acute inflammatory disease. We look forward to sharing additional data from this trial later in the year and are also planning to meet with the FDA to discuss the design of a Phase 3 trial,\" said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. \"In addition, we are excited about KOURAGE, our Phase 2 trial in patients with severe AKI. We are enrolling patients and opening new sites and expect to share topline data from this study in 2025.\"\nRecent Clinical Updates and Anticipated Milestones:\nPositive topline data announced from Phase 2b CARPO trial: In June 2024, CalciMedica hosted a conference call to review positive topline data from CARPO, the Company's randomized, double-blind, placebo-controlled Phase 2b trial of Auxora™ in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The trial met its primary objective with a statistically significant dose response in median time to solid food tolerance in a pre-specified subgroup of hyper-inflamed patients with AP as well as in reduction of severe organ failure across the full patient population. Full data from the trial are expected in the second half of 2024 and the Company plans to present them at future medical meetings. Furth...